Print
Health Care

Alcami CEO Talks Expansion

By Audrey Elsberry, posted Nov 21, 2023
Alcami recently expanded one of its Wilmington facilities to make room for more of its stability chambers, which are filling up according to Alcami CEO William Humphries. (Photo courtesy of Alcami)
Alcami, a pharmaceutical manufacturing company started in Wilmington 40 years ago, is expanding its facilities in the Port City and around the state.

Alcami performs a suite of services for outside pharmaceutical companies. Its CEO William Humphries compared it to a three-legged stool. The three legs are the company's drug lab operations, bio-storage and validation and calibration — basically quality control. Its locations include Wilmington, Research Triangle Park, Charleston, St. Louis and two locations in New England.

Of Alcami’s campuses across the eastern U.S., it employs the bulk of its employees in Wilmington, Humphries said. The company expanded one of its Wilmington facilities by 20,000 square feet in October between its packaging and warehouse storage space.

Stability chambers, used to ensure the correct storage environment for pharmaceutical products, are becoming a key offering for Alcami, Humphries said. The stability chambers in the Wilmington facility were filling up, so the expansion allowed for that service to continue to grow.

Alcami uses its Wilmington campus for analytical development, stability, microbiology, routine testing, oral solid dose manufacturing and formulation development along with packing and labeling.

"We have a whole building that's almost entire laboratory space where we do some of our biggest and best testing,” Humphries said. “From analytical testing to microchemistry, release testing — super important. That location is really strategic.”

He plans to keep the Wilmington campus at 2320 Scientific Drive growing in both space and personnel. Humphries said he sees strong hiring out of Wilmington to continue. A large portion of local hires are University of North Carolina Wilmington graduates.

The pharmaceutical CDMO, or Contract Development and Manufacturing Organization, has also recently expanded its bio-storage business by acquiring Massachusetts-based Masy BioServices in 2021, Humphries said.

Since then, Alcami took that bio-storage business back to its home state of North Carolina, breaking ground on a 65,000-square-foot storage facility in Garner. Humphries said he hopes to capitalize on companies that don’t account for warehouse and storage space in their plans for new offices.

The Garner facility will be able to accommodate many different storage requirements for different drugs, from room temperature storage to large tanks of liquid nitrogen to store human cells. Humphries expects to move the first pallet of storage materials in late December.

As for what will be stored at the facility, it ranges from packaging components like tubes and bottles that can be stored at room temperature to active pharmaceutical ingredients used in drugs, Humphries said.

Bringing the New England facility down to the Research Triangle area was motivated by the number of offices Alcami has in the state, and its access to the Port of Wilmington, airports in Raleigh and Wilmington and the slew of highways intersecting the area.

Other areas of expansion for the company include injectable drug manufacturing, Humphries said. Injectable drugs have been dominating the news cycle lately, as Ozempic, an injectable initially intended to help those with type 2 diabetes, has been found to help in weight loss. Another injectable, Wegovy, is specifically marketed for weight loss and has been equally touted in the media.

Alcami works in both small and large-molecule medications, Humphries said. The Wilmington lab specializes in small-molecule, or meds in pill form, but elsewhere Alcami manufactures medication that needs to be injected, which is categorized as large-molecule. 

Humphries said he wants to be ready to meet injectable demand as these drugs saturate the market. Alcami can help large pharmaceutical companies manufacture these drugs to conduct clinical trials and help small and mid-size companies mass manufacture large molecule, injectable drugs, he said.
Ico insights

INSIGHTS

SPONSORS' CONTENT
Untitleddesign13 162533932

Why Buyers Should Seek Well-Run Businesses, Not Fire Sales: The Misconception About “Good Deals” in M&A

Tully Ryan - Murphy Business Sales
Gretchen roberts 2021

From Contracts to Offshoring: 7 Powerful Gross Margin Growth Levers

Gretchen Roberts - Red Bike Advisors
Jane

It’s Child’s Play

Jane Morrow - Smart Start of New Hanover County

Trending News

Tech Wilmington: Upcoming Events Calendar

Staff Reports - Feb 5, 2025

Vantaca Hires Four Executives With Decades Of Scale-up Experience

Staff Reports - Feb 4, 2025

NCino Appoints New CEO

Staff Reports - Feb 3, 2025

City Leaders Approve Special Use Permit For Midtown Pickleball Facility

Emma Dill - Feb 5, 2025

Workforce Housing Panel: Some Steps Taken, But Problem Getting Worse

Emma Dill - Feb 4, 2025

In The Current Issue

Hospital Chief: High-dollar Projects In Works

Ongoing growth is the prognosis for Novant Health’s activities this year in the Cape Fear region, a top official at Novant Health New Hanove...


Bakatsias Restaurant Group Grows Locally

Giorgios Bakatsias and his company – Giorgios Hospitality Group – will also be opening Tomikosan sushi bar at Lumina Station, bringing the g...


Groups Share This Year’s To-do Lists

For the Book on Business, the Business Journal asks several of the region’s economic development groups and organizations for a recap of wha...

Book On Business

The 2024 WilmingtonBiz: Book on Business is an annual publication showcasing the Wilmington region as a center of business.

Order Your Copy Today!


Galleries

Videos

2024 Power Breakfast: The Next Season